drugset / Trial / NCT04811651

Umbilical Cord-derived Mesenchymal Stem Cells for Ischemic Stroke

NCT04811651

Phase 2 Completed 156 enrolled General Hospital of Shenyang Military Region
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a doble blind, placebo controlled clinical trial to assess safety and efficacy of intravenous administration of Umbilical cord-derived Mesenchymal Stem cells in patients with ischemic stroke within 6 months of onset.

Timeline

Start
2021-03-15
Primary completion
2024-07-30
Completion
2024-07-30

Drugs

EvaluationDrugModalityDoseRoute
Subject mesenchymal stem cells Cell therapy 1e+08 cells Intravenous

Indications